Mereo BioPharma provides update on recent program developments

Mereo BioPharma Group (MREO) provided an update on recent program developments and third quarter 2023 financial information. On October 14, 2023, Ultragenyx Pharmaceutical (RARE) and Mereo BioPharma Group plc announced interim data from the Phase 2 portion of the Phase 2/3 Orbit study demonstrating that treatment with setrusumab achieved a 67% reduction in annualized fracture rate in patients with osteogenesis imperfecta with at least 6 months of follow-up and continues to demonstrate ongoing and meaningful improvements in lumbar spine bone mineral density The Phase 3 portion of the study is currently enrolling approximately 195 patients at 50 sites across 12 countries…Additionally, University of Alabama at Birmingham and the Company are reporting on the ATALANTa study, a multi-center, double-blind, placebo-controlled, proof-of-concept investigator-led study run by Professor Mark Dransfield, Director of the Division of Pulmonary, Allergy and Critical Care, UAB, in collaboration with Mereo…